Achieve Life Sciences Names Goldberg CEO, Secures $354M Financing for Cytisinicline Launch
Event summary
- Andrew D. Goldberg, MD, appointed CEO and Board member of Achieve Life Sciences effective April 16, 2026.
- Company secures up to $354M in financing ($180M upfront, $174M dependent on milestone warrants).
- Goldberg brings dual board certification in Critical Care and Emergency Medicine, plus healthcare investment experience.
- Two new healthcare leaders, Lucian Iancovici, MD, and Aaron E. Royston, MD, join the Board.
- Cytisinicline NDA review ongoing with PDUFA date set for June 20, 2026.
The big picture
Achieve Life Sciences is positioning itself for a potential breakthrough in nicotine dependence treatment with the appointment of Andrew D. Goldberg as CEO and a significant financing round. The move comes as the company awaits FDA decision on its cytisinicline NDA, targeting a market with substantial unmet needs in both smoking and vaping cessation. Goldberg's dual expertise in clinical medicine and healthcare investment could be pivotal in navigating the complexities of commercializing a new treatment in this space.
What we're watching
- Regulatory Approval
- Whether the FDA will approve cytisinicline by the June 20, 2026 PDUFA date, clearing the path for commercialization.
- Commercial Strategy
- How Goldberg will execute the commercial strategy for cytisinicline, leveraging his healthcare investment and physician background.
- Market Opportunity
- The pace at which Achieve can capture market share in nicotine dependence treatment, addressing both smoking and vaping.
Related topics